MT2A and ovarian cancer: Bioinformatic analysis revealed that NDRG1, CYBRD1, and MT2A expressions upregulated and were associated with poor prognosis of ovarian cancer patients in the platinum-based treatment group, whereas upregulation of ERBB4 and ANK3 correlated with improved prognosis.